EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Temperature‐controlled radiofrequency ablation for the treatment of chronic rhinitis: Two‐year outcomes from a prospective multicenter trial

Masayoshi Takashima, J Pablo Stolovitzky, Randall A Ow, Stacey L Silvers, Chad M McDuffie, Marc Dean, Ahmad R Sedaghat iD, Bobby A Tajudeen

International Forum of Allergy & Rhinology · 2024

DOI: 10.1002/alr.23315 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Masayoshi Takashima und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Otolaryngology-Head and Neck Surgery, Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Rhinitis, Radiofrequency Ablation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Aerin Medical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Minimally invasive temperature‐controlled radiofrequency (TCRF) ablation of the posterior nasal nerve (PNN) demonstrated a significant larger treatment effect on the symptom burden of chronic rhinitis patients than a sham control (no energy delivery) at the 3‐month primary endpoint of this trial.

Methods

Two‐year posttreatment outcomes for patients treated in a prospective, multicenter, patient‐blinded randomized controlled trial were determined by combining the index active treatment‐arm and index control‐arm crossover patients into a single group (after the primary endpoint) to evaluate the treatment effect durability and long‐term effects on concomitant chronic rhinitis medication usage.

Results

The mean baseline reflective total nasal symptom score (rTNSS) was 8.2 (95% confidence interval [CI], 7.9–8.6; N = 104). At 2 years ( N = 79), the mean change in rTNSS was −5.3 (95% CI, −5.8 to −4.8; p < 0.001; 64.6% improvement). The 2‐year responder rate (≥30% improvement in rTNSS) was 87.3% (95% CI, 78.0–93.8). All four components of the rTNSS (rhinorrhea, congestion, sneezing, and nasal itching) showed significant improvement over baseline, with rhinorrhea and congestion showing the most improvement. Postnasal drip and cough symptoms were also significantly improved. At 2 years, 81.0% (95% CI, 70.6–89.0) reported a minimal clinically important difference of ≥0.4‐point improvement in the mini‐rhinoconjunctivitis quality of life questionnaire score. Of 56 patients using chronic rhinitis medications at baseline, 25 of 56 (44.6%) either stopped all medication use (7/56 [12.5%]) or stopped/decreased (18/56 [32.1%]) use of ≥1 medication class at 2 years. No serious adverse events related to the device/procedure were reported over 2 years. To determine the potential effect of patients who left the trial over 2 years on the responder rate, the responder statuses of the 14 patients with follow‐up data who were lost to follow‐up/withdrew/died were imputed by the last observation carried forward and the responder statuses of all nine patients who had an additional nasal procedure were imputed to nonresponder, resulting in a 2‐year responder rate of 79.4% (95% CI, 70.3–86.8).

Conclusion

TCRF ablation of the PNN is safe and resulted in a significant and sustained reduction in chronic rhinitis symptom burden through 2 years and a substantial reduction in concomitant medication burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinitisRadiofrequency AblationHumansFemaleMaleMiddle AgedChronic DiseaseTreatment OutcomeProspective StudiesAdultAgedQuality of LifeTemperature

Stichwörter der Autor:innen

RQLQablationcongestionneurolysisposterior nasal nerveradiofrequency rhinitisrhinorrhea

Autor:innen und Institutionen

  • The Department of Otolaryngology-Head and Neck Surgery, Houston Methodist Hospital, Houston, Texas, USA.
  • The Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Sacramento Ear Nose and Throat Medical and Surgical Group, Roseville, California, USA.
  • Madison ENT & Facial Plastic Surgery, New York, New York, USA.
  • Ear, Nose, and Throat Associates of Texas, McKinney, Texas, USA.
  • Ear & Sinus Institute, Fort Worth, Texas, USA.

ORCID-Profile: Ahmad R Sedaghat

Förderung

  • Aerin Medical

Zitieren

APA

Takashima, M., Stolovitzky, J. P., Ow, R. A., Silvers, S. L., McDuffie, C. M., Dean, M., Sedaghat, A. R., & Tajudeen, B. A. (2024). Temperature‐controlled radiofrequency ablation for the treatment of chronic rhinitis: Two‐year outcomes from a prospective multicenter trial. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23315

Vancouver

Takashima M, Stolovitzky JP, Ow RA, Silvers SL, McDuffie CM, Dean M, et al. Temperature‐controlled radiofrequency ablation for the treatment of chronic rhinitis: Two‐year outcomes from a prospective multicenter trial. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23315

BibTeX
@article{Takashima2024,
  author = {Takashima, Masayoshi and Stolovitzky, J Pablo and Ow, Randall A and Silvers, Stacey L and McDuffie, Chad M and Dean, Marc and Sedaghat, Ahmad R and Tajudeen, Bobby A},
  title = {Temperature‐controlled radiofrequency ablation for the treatment of chronic rhinitis: Two‐year outcomes from a prospective multicenter trial},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  doi = {10.1002/alr.23315}
}
Kostenlos starten →